ApoPharma is focused on the development of products that can help people who have debilitating and life-threatening conditions that are caused by or worsened by iron.

our focus is on the discovery and development of new molecules in 2 key areas with the goal of providing much needed treatment options where none currently exist. 
1) Haematological conditions where iron plays a role;
2) Neurodegenerative diseases;

ApoPharma evolved from the Innovative Drug Division of the Apotex family of companies. Our research focus is on the use of medicines to treat disorders caused or worsened by excessive iron or faulty processing of iron in cells in the body. These disorders include both generalized iron overload, which affects patients who must undergo repeated blood transfusions, and localized iron dysregulation in the brain, which underlies a number of neurological disorders such as pantothenate kinase-associated neurodegeneration and Parkinson’s disease

Please visit our exhibition booth – ApoPharma
Visit our website at